Estimation of cancer risk based on the organ-absorbed dose is underway for the Japanese Epidemiological Study on Low-Dose Radiation Effects (J-EPISODE). The reconstruction method for the organ-absorbed dose follows the approach adopted in the IARC 15-Country Collaborative Study, which examined the dosemeter response to photon exposure for the old film badge (FB) type, a multi-element FB and a thermoluminescence dosemeter. Until 2000, the dosemeters used in Japan were almost the same in the IARC study, so IARC study data could be used as they were. However, since 2000, the type of dosemeter has been replaced with active personal dosemeters (hereafter called electronic personal dosemeters), radio-photoluminescent glass dosemeters (Glass badge) and optically stimulated luminescence dosemeters (Luminess badge). Hence, it was necessary to collect these data again. A dosemeter response experiment was conducted using a device that irradiated an anthropomorphic phantom in the Japan Atomic Energy Agency calibration laboratories. The aim of the paper is to provide a conversion factor from reading in terms of Hp(10) to air kerma for realistic conditions for further conversion from air kerma to organ-absorbed dose. The obtained dosemeter responses for the dosemeter types currently used in Japan were consistent with those in the IARC study. These data will be utilized for J-EPISODE in reconstructing the organ-absorbed dose.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366797 | PMC |
| http://dx.doi.org/10.1093/rpd/ncaa051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validation of dosimetry programs (Olinda & IDAC) for evaluation of absorbed dose in LuPSMA therapy of metastatic castration-resistant prostate cancer (mCRPC) using Monte Carlo simulation.
EJNMMI Phys
December 2024
Medical Physics Group, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Purpose: Clinical trials have yielded promising results for Lutetium Prostate Specific Membrane Antigen (Lu-PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC) patients. However, the development of precise methods for internal dosimetry and accurate dose estimation has been considered ongoing research. This study aimed to calculate the absorbed dose to the critical organs and metastasis regions using GATE 9.
View Article and Find Full Text PDFUpdated findings on temporal variation in radiation-effects on cancer mortality in an international cohort of nuclear workers (INWORKS).
Eur J Epidemiol
November 2024
International Agency for Research on Cancer (IARC/WHO), Lyon, France.
The International Nuclear Workers Study (INWORKS) contributes knowledge on the dose-response association between predominantly low dose, low dose rate occupational exposures to penetrating forms of ionizing radiation and cause-specific mortality. By extending follow-up of 309,932 radiation workers from France (1968-2014), the United Kingdom (1955-2012), and the United States (1944-2016) we increased support for analyses of temporal variation in radiation-cancer mortality associations. Here, we examine whether age at exposure, time since exposure, or attained age separately modify associations between radiation and mortality from all solid cancers, solid cancers excluding lung cancer, lung cancer, and lymphohematopoietic cancers.
View Article and Find Full Text PDFLutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study.
Theranostics
September 2024
Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Article Synopsis
- There is a critical need for new treatments for recurrent salivary gland cancers, with current options being limited.
- A pilot study tested the safety and effectiveness of [Lu]Lu-PSMA-I&T therapy on patients with adenoid cystic carcinoma (AdCC) and salivary duct carcinoma (SDC), aiming to include 10 AdCC and 5 SDC patients.
- Results showed that 67% of AdCC patients were eligible, but there were no objective responses; however, some exhibited stable disease for over 6 months, and the study faced challenges with high screen failure rates in SDC patients.
Results from a phase I study of 4--[131I]iodo-phenylalanine ([I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1).
Neurooncol Adv
July 2024
ABX - CRO Advanced Pharmaceutical Services Forschungsgesellschaft, Dresden, Germany.
Background: Glioblastoma (GBM), the most common malignant brain tumor, is associated with devastating outcomes. IPAX-1 was a multicenter, open-label, single-arm phase I study to evaluate carrier-added 4--[I]iodo-phenylalanine ([I]IPA) plus external radiation therapy (XRT) in recurrent GBM.
Methods: A total of 10 adults with recurrent GBM who had received first-line debulking surgery plus radio-chemotherapy, were randomized to a single-dose regimen (1f; I-IPA 2 GBq before XRT); a fractionated parallel dose regimen (3f-p; 3 I-IPA 670 MBq fractions, in parallel with second-line XRT), or a fractionated sequential dose regimen (3f-s; 3 I-IPA 670 MBq fractions before and after XRT).
Theranostic Intratumoral Convection-Enhanced Delivery of I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry.
J Nucl Med
September 2024
Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York; and.
Diffuse intrinsic pontine glioma (DIPG) is a rare childhood malignancy with poor prognosis. There are no effective treatment options other than external beam therapy. We conducted a pilot, first-in-human study using I-omburtamab imaging and theranostics as a therapeutic approach using a localized convection-enhanced delivery (CED) technique for administering radiolabeled antibody.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!